Synonym
RSM-932A; RSM 932A; RSM932A; TCD 717; TCD717; TCD-717.
IUPAC/Chemical Name
1,1'-([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)quinolin-1-ium) bromide
InChi Key
DGBVSSXGHKAASQ-UHFFFAOYSA-L
InChi Code
InChI=1S/C46H38Cl2N4.2BrH/c1-49(39-23-19-37(47)20-24-39)43-27-29-51(45-9-5-3-7-41(43)45)31-33-11-15-35(16-12-33)36-17-13-34(14-18-36)32-52-30-28-44(42-8-4-6-10-46(42)52)50(2)40-25-21-38(48)22-26-40;;/h3-30H,31-32H2,1-2H3;2*1H/q+2;;/p-2
SMILES Code
CN(C1=CC=C(Cl)C=C1)C(C2=C3C=CC=C2)=CC=[N+]3CC4=CC=C(C5=CC=C(C[N+]6=CC=C(N(C7=CC=C(Cl)C=C7)C)C8=C6C=CC=C8)C=C5)C=C4.[Br-].[Br-]
Appearance
White solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
850807-63-5 ( RSM-932A)
850993-73-6 ( RSM-932A cation)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
877.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lacal JC, Campos JM. Preclinical characterization of RSM-932A, a novel
anticancer drug targeting the human choline kinase alpha, an enzyme involved in
increased lipid metabolism of cancer cells. Mol Cancer Ther. 2015 Jan;14(1):31-9.
doi: 10.1158/1535-7163.MCT-14-0531. Epub 2014 Dec 8. PubMed PMID: 25487918.
2: Zimmerman T, Moneriz C, Diez A, Bautista JM, Gómez Del Pulgar T, Cebrián A,
Lacal JC. Antiplasmodial activity and mechanism of action of RSM-932A, a
promising synergistic inhibitor of Plasmodium falciparum choline kinase.
Antimicrob Agents Chemother. 2013 Dec;57(12):5878-88. doi: 10.1128/AAC.00920-13.
Epub 2013 Sep 16. PubMed PMID: 24041883; PubMed Central PMCID: PMC3837925.
3: Zimmerman T, Chasten V, Lacal JC, Ibrahim SA. Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae. Sci Rep. 2020 Sep 22;10(1):15418. doi: 10.1038/s41598-020-72165-6. PMID: 32963303; PMCID: PMC7508948.
4: Ghorbani P, Kim SY, Smith TKT, Minarrieta L, Robert-Gostlin V, Kilgour MK, Ilijevska M, Alecu I, Snider SA, Margison KD, Nunes JRC, Woo D, Pember C, O'Dwyer C, Ouellette J, Kotchetkov P, St-Pierre J, Bennett SAL, Lacoste B, Blais A, Nair MG, Fullerton MD. Choline metabolism underpins macrophage IL-4 polarization and RELMα up-regulation in helminth infection. PLoS Pathog. 2023 Sep 25;19(9):e1011658. doi: 10.1371/journal.ppat.1011658. PMID: 37747879; PMCID: PMC10553840.
